Stephen Willey

Q: How accurate are Stephen Willey's stock ratings?

About 49% of Stephen's ratings were profitable over a one-year hold, with an average return of -2.4% per rating, measured by 13Foresight from historical prices.

Q: How is Stephen ranked?

Stephen Willey is ranked #2328 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Stifel Nicolaus

Wall Street Analyst

★★☆☆☆

#2328

on 13Foresight · ranked by our own returns

49%

Success Rate

-2.4%

Average Return

48 of 97 calls profitable · +16.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 49% of Stephen Willey's ratings turned a profit when each position was held for 1 year — averaging -2.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

120 Buy 16 Hold 0 Sell

Stephen's Stock Coverage 47 ratings · 2026-11-10

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
INCY Incyte	Oct 30, 2026	BUY	Strong Buy -5.9% avg upside 49 analysts	$157.00 30.46% Upside	-0.6%	·
EXEL Exelixis	Oct 30, 2026	HOLD	Buy -34.0% avg upside 34 analysts	$51.00 26.55% Downside	+3.4%	·
BCAX Bicara Therapeutics Inc.	Oct 29, 2026	BUY	Strong Buy +247.0% avg upside 16 analysts	$45.00 392.79% Upside	-3.2%	·
ZYME Zymeworks	Oct 28, 2026	BUY	Strong Buy +18.4% avg upside 26 analysts	$46.00 60.83% Upside	+2.5%	·
CELC Celcuity	Oct 26, 2026	BUY	Strong Buy +82.7% avg upside 18 analysts	$150.00 117.03% Upside	+1.5%	·
CMPX Compass Therapeutics	Oct 26, 2026	BUY	Strong Buy +831.6% avg upside 20 analysts	$6.00 662.89% Upside	+3.0%	·
CBIO Crescent Biopharma	Oct 16, 2026	BUY	Strong Buy +73.7% avg upside 17 analysts	$28.00 107.72% Upside	+14.4%	·
NRIX Nurix Therapeutics	Oct 13, 2026	BUY	Strong Buy +22.5% avg upside 28 analysts	$41.00 53.07% Upside	-30.9%	·
OABI OmniAb	Oct 07, 2026	BUY	Strong Buy +59.0% avg upside 10 analysts	$9.00 76.05% Upside	+8.6%	·
CGEN Compugen	Oct 06, 2026	BUY	Strong Buy +173.4% avg upside 8 analysts	$4.00 101.93% Upside	-13.5%	·
VOR Vor Biopharma	Sep 28, 2026	BUY	Strong Buy +117.7% avg upside 19 analysts	$40.00 103.32% Upside	+12.4%	·
NKTX Nkarta	Sep 28, 2026	BUY	Strong Buy +1080.5% avg upside 16 analysts	$10.00 540.96% Upside	-35.2%	·
LYEL Lyell Immunopharma	Sep 11, 2026	BUY	Strong Buy +151.1% avg upside 12 analysts	$36.00 226.11% Upside	+28.9%	·
PYXS Pyxis Oncology	Aug 17, 2026	BUY	Strong Buy +349.6% avg upside 15 analysts	$7.00 286.71% Upside	-41.6%	·
SNDX Syndax Pharmaceuticals	Aug 14, 2026	BUY	Strong Buy +155.4% avg upside 27 analysts	$40.00 193.04% Upside	-51.9%	·
CADL Candel Therapeutics	Aug 14, 2026	BUY	Strong Buy +134.0% avg upside 12 analysts	$22.00 164.02% Upside	-25.9%	·
MGNX MacroGenics	Aug 14, 2026	HOLD	Buy +638.9% avg upside 25 analysts	$4.00 66.62% Upside	-44.8%	·
JANX Janux Therapeutics Inc	Aug 11, 2026	BUY	Strong Buy +159.3% avg upside 22 analysts	$35.00 100.41% Upside	+5.9%	·
ABCL AbCellera Biologics	Aug 06, 2026	BUY	Strong Buy +33.0% avg upside 18 analysts	$9.00 26.68% Downside	+70.4%	·
IRON Disc Medicine	Jul 31, 2026	BUY	Strong Buy +23.4% avg upside 21 analysts	$111.00 37.40% Upside	+1.9%	·
INSM Insmed	Jul 17, 2026	BUY	Strong Buy +51.3% avg upside 37 analysts	$200.00 77.66% Upside	+5.6%	·
ABEO Abeona Therapeutics	Mar 18, 2026	BUY	Strong Buy +295.1% avg upside 18 analysts	$17.00 290.81% Upside	-6.6%	·
XFOR X4 Pharmaceuticals	Nov 05, 2025	BUY	Strong Buy +613.0% avg upside 16 analysts	$7.50 123.79% Upside	-13.5%	·
GYRE Gyre Therapeutics	Jun 24, 2025	BUY	Strong Buy +354.5% avg upside 15 analysts	$28.00 514.66% Upside	-14.8%	·
BOLT Bolt Biotherapeutics	May 13, 2025	HOLD	Buy +294.5% avg upside 7 analysts	$20.00 203.55% Upside	-30.0%	·
GERN Geron	Mar 12, 2025	BUY	Strong Buy +371.7% avg upside 19 analysts	$4.00 347.21% Upside	-9.6%	·
CUE Cue Biopharma	Nov 15, 2024	BUY	Strong Buy -10.7% avg upside 10 analysts	$4.00 80.90% Downside	-49.4%	·
LITS Lite Strategy	May 14, 2024	HOLD	Strong Buy +865.4% avg upside 13 analysts	$6.00 435.64% Upside	-29.8%	·
SQZB SQZ Biotechnologies	Aug 11, 2022	BUY	Strong Buy +102677.7% avg upside 7 analysts	$14.00 58233.35% Upside	·	·
SPRY ARS Pharmaceuticals	May 13, 2022	HOLD	Strong Buy +492.7% avg upside 12 analysts	$5.00 47.93% Upside	+171.6%	·
IVVD Invivyd	May 13, 2022	HOLD	Buy +1291.0% avg upside 8 analysts	$5.00 759.56% Upside	-47.1%	·
INO Inovio Pharmaceuticals	May 11, 2022	HOLD	Buy +1300.8% avg upside 19 analysts	$1.00 66.03% Upside	-56.9%	·
SPRO Spero Therapeutics	Mar 12, 2021	BUY	Buy +1102.8% avg upside 13 analysts	$27.00 2447.23% Upside	-50.1%	·
LXRX Lexicon Pharmaceuticals	Mar 11, 2021	HOLD	Buy +216.5% avg upside 10 analysts	$6.00 322.46% Upside	-69.9%	·
XENE Xenon	Mar 29, 2019	BUY	Strong Buy +53.0% avg upside 28 analysts	$21.00 43.86% Downside	+8.3%	·
TARA Protara Therapeutics	Mar 14, 2019	HOLD	Strong Buy +1907.3% avg upside 21 analysts	$160.00 6351.68% Upside	·	·
BMRN BioMarin Pharmaceutical	Aug 06, 2018	BUY	Strong Buy +63.6% avg upside 52 analysts	$114.00 94.89% Upside	-22.4%	·
IONS Ionis Pharmaceuticals	Aug 06, 2018	HOLD	Strong Buy +74.1% avg upside 44 analysts	$48.00 10.21% Upside	+46.8%	·
ALNY Alnylam Pharma	Aug 06, 2018	BUY	Strong Buy +76.3% avg upside 53 analysts	$125.00 24.18% Downside	-20.1%	·
INVA Innoviva	Apr 27, 2018	HOLD	Strong Buy +37.9% avg upside 13 analysts	$16.00 24.58% Downside	-3.2%	·
HCM HUTCHMED	Apr 04, 2017	BUY	Buy +135.4% avg upside 9 analysts	$26.00 97.70% Upside	+55.0%	·
TVRD Tvardi Therapeutics	Feb 02, 2017	BUY	Strong Buy +2090.0% avg upside 24 analysts	$24.00 2927.29% Upside	·	·
RNAC Cartesian Therapeutics	Dec 02, 2016	BUY	Strong Buy +378.5% avg upside 19 analysts	$23.00 254.42% Upside	·	·
JAZZ Jazz Pharmaceuticals	May 31, 2016	BUY	Strong Buy +16.2% avg upside 36 analysts	$200.00 7.46% Downside	-4.0%	·
ACHV Achieve Life Sciences	Dec 02, 2015	HOLD	Strong Buy +128.6% avg upside 16 analysts	—	·	·
ABUS Arbutus Biopharma	Nov 07, 2014	BUY	Strong Buy +109.9% avg upside 15 analysts	$26.00 517.65% Upside	-64.6%	·
RIGL Rigel	Apr 08, 2013	BUY	Strong Buy -47.4% avg upside 17 analysts	$7.00 86.35% Downside	-24.7%	·

🔒 42 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Stephen Willey — Frequently Asked Questions

How accurate are Stephen Willey's stock ratings?

Based on the calls 13Foresight could measure, about 49% of Stephen's ratings were profitable over a one-year hold, with an average return of -2.4% per rating, or +16.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Stephen ranked on 13Foresight?

Stephen Willey is currently ranked #2328 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Stephen cover?

Stephen most recently has ratings on INCY, EXEL, BCAX, ZYME, CELC, CMPX, CBIO, NRIX, OABI, CGEN, VOR, NKTX and 35 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Stephen Willey

Rating Distribution

Welcome to 13Foresight!